Abstract 89P
Background
Current treatment strategies have improved gastric cancer (GC) patient survival yet disease progression risks remain considerable. Attention is directed to immune homeostasis mediators as indicators of therapy impact. Study aimed at investigating immunomodulatory cells & cytokines profiles in chemotherapy-naïve and Neoadjuvant chemotherapy (NACT) treated GC patients.
Methods
Prospective cohorts of 46 GC patients scheduled for surgical tumor excision first (CTn; n=18) or following NACT treatment (NACT; n=28) were included. NACT were grouped according to Mandard’s criteria into Responders (R;TRG1- 3;n=14) and Non-Responders(NR;TRG4-5;n=14). Peripheral blood samples for PBMCs and serum isolation were collected before surgery. Characterization of immune populations (cytotoxic CD3+CD8+ T-cells, CD4+FOXP3+ T-regs, CD3- CD16+CD56mid+ NKcells, CD3+CD16+ NKTcells & CD14+CD16-/CD14+CD16+/CD14-CD16+monocytes) & serum cytokines (IL-2, IL-4, IL-6, IL- 10, TNFa, IL-17a; by Cytometric Bead Arrays) was performed with FACS.
Results
NACT patient profiles revealed immune status differences between R and NR patients. R were defined by upregulated Tregs (p=0.016 vs NR), antitumor NKcells and intermediate (CD14+CD16+) monocytes (p=0.031 vs NR) and a concomitant profile of moderate increase of cytokines IL2, IL4, IL6 and IL10. In contrast, NR were characterized by increased classical (CD14+CD16-) monocytes, cytotoxic Tcells and NKTcells. NR also showed a reduction of IL2 and anti-inflammatory cytokines IL10 and IL4. CTn patients exhibited a similar to NR immunoprofile of increased cytotoxic populations, but also relatively increased Tregs, whilst cytokine patterns revealed predominance of pro- inflammatory TNFa and elevated IL4 and IL17a.
Conclusions
Responders were characterized by abundance of contributing to immunocompetence immune cells & antitumor acting cytokines whilst tumour progression in CTn & chemoresistant patients correlated with predominance of cytotoxic immunosurveilance populations & deprivation of immunoregulatory cytokines. Evidence highlights the immunomodulators profilling potential towards personalizing GC patient management.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
National and Kapodistrian University of Athens, Greece.
Funding
ERAPerMed 2019-275 (GRAMMY). ERAPerMed - Joint Transnational Call for Proposals (2019) for “Personalised Medicine: Multidisciplinary Research Towards Implementation”.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Heterogeneous characteristics of KRAS mutation subtypes in surgically resected lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - ATRX-deficient IDH-wildtype adult high-grade gliomas display novel, clinically relevant genetic patterns by comprehensive genomic profiling
Presenter: Gábor Bedics
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
Presenter: Silvia Teresa Riva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations
Presenter: Greydon Arthur
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype
Presenter: Mohamed abd naceur AMMAR
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Unraveling methylation signatures in RAS/BRAF wild-type colorectal cancer patients to identify predictive biomarkers for anti-epidermal growth factor receptor therapy
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - Spindle cell sarcomas with tyrosine kinase rearrangement
Presenter: Lenka Krsková
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Presenter: Ioanna Mavrommatis
Session: Cocktail & Poster Display session
Resources:
Abstract